Modelling the economic and health consequences of cardiac resynchronization therapy in the UK

References

• British Heart Foundation Statistics. Coronary heart disease statistics: heart failure supplement 2002. Available from http://www.heartstats.org/homepage.asp/ [last accessed 17 Feb 2006]
   Google Scholar
• British Heart Foundation Statistics. Deaths from heart failure, by sex and age and country, 2001, UK. Available from http://www.heartstats.org/homepage.asp/ [last accessed 17 Feb 2006]
   Google Scholar
• Lacey L, Tabberer M. Economic burden of post-acute myocardial infarction heart failure in the United Kingdom. Eur J Heart Fail 2005;7:677–83
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154–235
   PubMed Web of Science ®Google Scholar
• Swedberg K, Cleland J, Dargie H, et al. ESC 2005 guideline for the diagnosis and treatment of chronic heart failure. Available from: http://www.escardio.org/NR/rdonlyres/8A2848B4-5DEB - 41B9-9A0A - 5B5A90494B64/0/CHFFullTextehi205FVFW170505.pdf/ [last accessed 19 March 2006]
   Google Scholar
• Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New Engl J Med 2004;350:2140–50
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. New Engl J Med 2002;346:1845–53
   PubMed Web of Science ®Google Scholar
• Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111–8
   PubMed Web of Science ®Google Scholar
• Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002;39:2026–33
   PubMed Web of Science ®Google Scholar
• Braunschweig F, Linde C, Gadler F, Ryden L. Reduction of hospital days by biventricular pacing. Eur J Heart Fail 2000;2:399–406
   PubMed Web of Science ®Google Scholar
• Banz K, Eucomed CRT Steering Committee. Cardiac resynchronization therapy (CRT) in heart failure – a model to assess the economic value of this new medical technology. Value Health 2005;8:128–39
   Google Scholar
• Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 2005;352:1539–49
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E, et al. The CARE-HF study (Cardiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001;3:3481–9
   Google Scholar
• Cleland JGF, Daubert JC, Freemantle N, et al. Baseline characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 2005;7:243–51
   PubMedGoogle Scholar
• Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323–32
   PubMed Web of Science ®Google Scholar
• McEwan P, Baboolal K, Conway P, Currie CJ. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clin Ther 2005;27:1834–46
   PubMed Web of Science ®Google Scholar
• Guest JF, Cookson RF. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999;15:597–610
   Google Scholar
• Cooper K, Davies R, Roderick P, et al. The development of a simulation model of the treatment of coronary heart disease. Health Care Manag Sci 2002;5:259–67
   PubMedGoogle Scholar
• McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006;22:121–9
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Boer R, Bhatnagar V, et al. A model for a smallpox-vaccination policy. New Engl J Med 2003;348:416–25
   PubMed Web of Science ®Google Scholar
• Davies R, Roderick P, Canning C, et al. The evaluation of screening policies for diabetic retinopathy using simulation. Diabetic Med 2002;19:762–70
   PubMed Web of Science ®Google Scholar
• Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA, 3rd ed. Boston: McGraw-Hill; 2003
   Google Scholar
• Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan [Pimobendan Multicenter Research Group]. Am Heart J 1992;124:1017–25
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005;7:243–51
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence. Guide to the methods of technology appraisal (N0515). Available from http://www.nice.org.uk/pdf/TAP_Methods.pdf/ [last assessed 11 Oct 2005]
   Google Scholar
• Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. Br Med J 2004;329:224–7
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail 2005;26:2681–8
   Web of Science ®Google Scholar
• Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2311–21
   PubMed Web of Science ®Google Scholar
• Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20(9):1016–24
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65–75
   PubMed Web of Science ®Google Scholar
• Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 2006;151:444–50
   Google Scholar
• Middel B, Bouma J, de Jongste, et al. Psychometric properties of the Minnesota Living with Heart Failure Questionnaire (MLHF-Q). Clin Rehabil 2001;15:489–500
   PubMed Web of Science ®Google Scholar